Inicio › Mieloma múltiple › Nueva York

Ensayos clínicos de Mieloma múltiple en Nueva York

75 estudios sobre Mieloma múltiple buscan participantes en Nueva York.

Ciudades en Nueva York

Texto oficial del estudio (inglés)

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site, Albany
Research Site, New York
Research Site, New York

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Memorial Sloan Kettering Cancer Center Mskcc, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT04973605

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Icahn School of Medicine at Mt. Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05652335

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Icahn School of Medicine at Mt. Sinai, New York
University of Rochester Medical Center, Rochester

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06500884

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Memorial Sloan Kettering, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07336472

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Roswell Park Cancer Institute, Buffalo
Mount Sinai Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
y 1 más

ReclutandoFase 4

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05201781

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07393282

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Mount Sinai Brooklyn, Brooklyn
NYU Winthrop, Mineola
Mount Sinai Chelsea, New York
y 3 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07258511

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Hematology-Oncology Associates of CNY, East Syracuse
Northwell Health Cancer Institute, Lake Success
NYU Langone Hospital Long Island, Mineola
y 3 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05552222

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Research Site, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07073547

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

New York Oncology Hematology, Albany
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
NYU Langone Health Manhattan, New York
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Mount Sinai Medical Center, New York
University of Rochester Medical Center, Rochester

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04634552

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

MSK Commack, Commack
MSK Westchester, Harrison
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05623020

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Tisch Cancer Institute at Mount Sinai, New York
Memorial Sloan-Kettering Cancer Center, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07116616

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Northwell Health Monter Cancer Center, Lake Success
Northern Westchester Hospital, Mount Kisco
Cohen Children's Medical Center, New Hyde Park
y 4 más

ReclutandoFase 2

Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Icahn School of Medicine at Mount Sinai /ID# 277844, New York
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946, New York
Weill Cornell Medicine Myeloma Center /ID# 278216, New York

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07095452

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT07648264

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Mount Sinai, The Tisch Cancer Instutute, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 sept 2026 · NCT04879043

Collection of Tissue Samples for Cancer Research

Roswell Park Cancer Institute, Buffalo

ReclutandoEstudio observacional

2 Months · Todos los sexos · Actualizado el 16 sept 2026 · NCT00900198

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Mount Sinai Hospital, New York
y 2 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06976476

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Weill Cornell Medical College, New York

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06615479

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06953960

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Icahn School of Medicine at Mount Sinai, New York

ReclutandoFase 2

Edades de 70 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06827860

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Roswell Park Cancer Institute, Buffalo
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06297226

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

New York Oncology Hematology, Albany

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06980480

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT06375044

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
North Shore University Hospital, Manhasset
Long Island Jewish Medical Center, New Hyde Park

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06152575

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

MSK Commack, Commack
MSK Westchester, Harrison
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT05020236

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

University of Rochester, Rochester
State University of New York Upstate Medical University, Syracuse
Upstate Cancer Center at Verona, Verona

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT04566328

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Research Site, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT06106945

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Roswell Park Comprehensive Cancer Center, Buffalo

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06292780

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Memorial Sloan-Kettering Cancer Center, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT05651932

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Roswell Park Cancer Institute, Buffalo

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT06627751

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
y 1 más

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT07105059

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site, Buffalo
Research Site, New York
Research Site, Stony Brook

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, Albany
Research Site, New Hyde Park
Research Site, New York
y 3 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Roswell Park Comprehensive Cancer Center, Buffalo

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 ago 2026 · NCT06622005

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Perlmutter Cancer Center at NYU Langone Hospital, Brooklyn
Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT07280013

Delayed Toxicities Post-CAR-T

Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 10 ago 2026 · NCT07665307

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

The Tisch Cancer Institute/Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT07284758

De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.